NeuroPace Raises $67M To Help Commercialize RNS System For Epilepsy
Executive Summary
The latest financing round will also support a new clinical trial of the RNS system for children with epilepsy.
You may also be interested in...
NeuroPace Seeks $75M In IPO
The California neuromodulation company filed a registration with the US Securities and Exchange Commission to sell common stock on NASDAQ under the ticker NPCE.
NeuroPace’s RNS For Epilepsy Becomes First FDA-Approved Responsive Neurostimulator
While standard neurostimulators are open-loop systems that stimulate continuously or intermittently according to preprogramming, RNS is a more targeted, closed-loop system that monitors brain activity in real time and provides electrical stimulation to interrupt troubling patterns that might cause a seizure.
Medtronic Earns CE Mark For Affera Ablation System, Touts New PFA Results
Results of the PULSED AF trial confirm that Medtronic’s PulseSelect pulsed field ablation is safe and effective for atrial fibrillation ablation. The company will likely incorporate PulseSelect into its Affera cardiac mapping and ablation system, which will soon be available in Europe.